NASDAQ:ANIP
Ani Pharmaceuticals Inc.
Ani Pharmaceuticals Inc.'s revenue grew 43.8% in fiscal 2025 to $883.4M while operating margin rose to 12.6%. Free cash flow was $171.4M, 19.4% of revenue, and the diluted share count rose 9.9%.Summary generated from Ani Pharmaceuticals Inc.'s SEC filings. Latest annual report filed Feb 27, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$883.4M
Revenue growth+43.8%
Revenue, 5-yr CAGR+33.5%
Gross marginn/a
Operating margin12.6%
Net margin8.9%
ROIC15.9%
Return on equity16.6%
Debt / equity0.57
Free cash flow$171.4M
FCF margin19.4%
Share count change+9.9%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 216 | 316 | 487 | 614 | 883 |
| Operating income | −40 | −35 | 47 | 1 | 111 |
| Net income | −43 | −48 | 19 | −19 | 78 |
| Free cash flow | 1 | −40 | 110 | 48 | 171 |
Recent filings
- 4Insider transaction report
Sep 30, 2026 - 4Insider transaction report
Sep 16, 2026 - 8-KDirector or officer change
Aug 24, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 7, 2026 - 8-KResults of operations and financial condition
Aug 7, 2026 - 8-KDirector or officer change
May 21, 2026 - 8-KRegulation FD disclosure
May 13, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 8, 2026